BioFocus Extends Collaboration with Usher III Initiative
News Jun 22, 2011
BioFocus has announced that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision.
BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a small-molecule therapy for Usher syndrome type III.
Under the terms of the extended agreement, BioFocus will further advance the project with the objective of delivering a pre-clinical candidate.
“The extension of this collaboration is testament to the quality of the scientific input that BioFocus offers its clients,” said Dr Chris Newton, Senior Vice President Galapagos Services. “The quality of the science at BioFocus enables it to sustain its position as a premier provider in drug discovery services.”
“We are pleased with the progress BioFocus has made thus far on discovering potential therapies for Usher syndrome. BioFocus’ approach fits very well with our aim of getting therapies into the clinic quickly and efficiently,” said Dr. David Saperstein, Scientific Director, Usher III Initiative, Inc.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018